Clinical Trial Update: Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating safety and efficacy of TH-302 CNS penetration in recurrent high-grade astrocytoma after bevacizumab, completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• High-grade Glioma

Drugs mentioned

• TH-302 (evofosfamide)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: HIGH GRADE GLIOMA | Phase 2 | Status: COMPLETED | Results posted: 2019-07-24